Besides patients carrying a BRAF mutation, MIF inhibitors could technically be effective on many tumor types harboring different mutation profiles, providing therapeutic alternatives to patients whose tumors do not correspond to classical targeted therapies. This evidence concerns the gene BRAF and neoplasm.